Lancet:新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平

2021-07-07 MedSci原创 MedSci原创

综上,Tirzepatide治疗2型糖尿病患者在血糖控制和体重方面有显著改善,且未增加低血糖风险。

tirzepatide是由礼来开发的一种每周一次的葡萄糖依赖性促胰岛素多肽(GIP,又名:胃抑制多肽)受体和胰高血糖素样肽-1(GLP-1)受体双重激动剂。GIP和GLP-1均为肠道分泌的激素,能够促进胰岛素分泌。tirzepatide将2种促胰岛素的作用整合至一个单分子中,代表了治疗2型糖尿病的一类新型药物。 值得一提的是,tirzepatide是第一个完成3期试验的双重GIP/GLP-1受体激动剂。2020年12月,礼来宣布III期SURPASS-1单药治疗研究达到了主要终点和次要终点:与安慰剂组相比,tirzepatide治疗组患者的糖化血红蛋白(A1C)和体重较基线显著下降。 在今年的虚拟研讨会上公布了GIP/GLP-1受体激动剂tirzepatide对仅靠饮食和运动无法充分控制的2型糖尿病患者的SURPASS-1和SURPASS-2试验的结果。最近,安慰剂对照的3期临床试验(SURPASS-1)的结果发表在《柳叶刀》Lancet杂志上。 研究人员在印度、日本、墨西哥和美国的52家医学研究中心和医院进行了为期40周的双盲、随机、安慰剂对照的3期试验。纳入仅靠饮食和运动不能充分控

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687760, encodeId=e8a9168e7604f, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Feb 07 03:13:22 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831231, encodeId=efb618312310a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Apr 17 09:13:22 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294043, encodeId=6e691294043e6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379420, encodeId=3f1c13e94206c, content=<a href='/topic/show?id=fddf803043' target=_blank style='color:#2F92EE;'>#GIP和GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8030, encryptionId=fddf803043, topicName=GIP和GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422760, encodeId=090f1422e6028, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627858, encodeId=fca0162e858f6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997417, encodeId=d6a999e417bf, content=<a href='/topic/show?id=f5cd1e48099' target=_blank style='color:#2F92EE;'>#tirzepatide#</a> 87-92%患者HbA1c小于7.0%,使用tirzepatide 5mg,平均HbA1c比基线下降1.87%;使用10mg、15mg,平均<a href='/topic/show?id=7d03849539' target=_blank style='color:#2F92EE;'>#HbA1c#</a>比基线下降1.89%与2.07%,而且体重降低7-10kg,太厉害!即使是低剂量,对于糖化血红蛋白降低水平也几乎是所有药物中最牛的。将来若再与<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>联用,几乎是攻无不克了!也可以说是近年来<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>领域划时代药物之一,这也表明,双靶点制剂,成为国际的热点,也是未来和希望所在,不仅仅是肿瘤,慢病同样如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17480, encryptionId=f5cd1e48099, topicName=tirzepatide), TopicDto(id=8495, encryptionId=7d03849539, topicName=HbA1c), TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Thu Jul 08 08:43:43 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034383, encodeId=f0b6103438391, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043685, encodeId=8a201043685c2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997362, encodeId=13fc99e36257, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jul 07 23:42:01 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1687760, encodeId=e8a9168e7604f, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Feb 07 03:13:22 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831231, encodeId=efb618312310a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Apr 17 09:13:22 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294043, encodeId=6e691294043e6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379420, encodeId=3f1c13e94206c, content=<a href='/topic/show?id=fddf803043' target=_blank style='color:#2F92EE;'>#GIP和GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8030, encryptionId=fddf803043, topicName=GIP和GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422760, encodeId=090f1422e6028, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627858, encodeId=fca0162e858f6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997417, encodeId=d6a999e417bf, content=<a href='/topic/show?id=f5cd1e48099' target=_blank style='color:#2F92EE;'>#tirzepatide#</a> 87-92%患者HbA1c小于7.0%,使用tirzepatide 5mg,平均HbA1c比基线下降1.87%;使用10mg、15mg,平均<a href='/topic/show?id=7d03849539' target=_blank style='color:#2F92EE;'>#HbA1c#</a>比基线下降1.89%与2.07%,而且体重降低7-10kg,太厉害!即使是低剂量,对于糖化血红蛋白降低水平也几乎是所有药物中最牛的。将来若再与<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>联用,几乎是攻无不克了!也可以说是近年来<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>领域划时代药物之一,这也表明,双靶点制剂,成为国际的热点,也是未来和希望所在,不仅仅是肿瘤,慢病同样如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17480, encryptionId=f5cd1e48099, topicName=tirzepatide), TopicDto(id=8495, encryptionId=7d03849539, topicName=HbA1c), TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Thu Jul 08 08:43:43 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034383, encodeId=f0b6103438391, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043685, encodeId=8a201043685c2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997362, encodeId=13fc99e36257, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jul 07 23:42:01 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2022-04-17 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1687760, encodeId=e8a9168e7604f, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Feb 07 03:13:22 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831231, encodeId=efb618312310a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Apr 17 09:13:22 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294043, encodeId=6e691294043e6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379420, encodeId=3f1c13e94206c, content=<a href='/topic/show?id=fddf803043' target=_blank style='color:#2F92EE;'>#GIP和GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8030, encryptionId=fddf803043, topicName=GIP和GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422760, encodeId=090f1422e6028, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627858, encodeId=fca0162e858f6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997417, encodeId=d6a999e417bf, content=<a href='/topic/show?id=f5cd1e48099' target=_blank style='color:#2F92EE;'>#tirzepatide#</a> 87-92%患者HbA1c小于7.0%,使用tirzepatide 5mg,平均HbA1c比基线下降1.87%;使用10mg、15mg,平均<a href='/topic/show?id=7d03849539' target=_blank style='color:#2F92EE;'>#HbA1c#</a>比基线下降1.89%与2.07%,而且体重降低7-10kg,太厉害!即使是低剂量,对于糖化血红蛋白降低水平也几乎是所有药物中最牛的。将来若再与<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>联用,几乎是攻无不克了!也可以说是近年来<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>领域划时代药物之一,这也表明,双靶点制剂,成为国际的热点,也是未来和希望所在,不仅仅是肿瘤,慢病同样如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17480, encryptionId=f5cd1e48099, topicName=tirzepatide), TopicDto(id=8495, encryptionId=7d03849539, topicName=HbA1c), TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Thu Jul 08 08:43:43 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034383, encodeId=f0b6103438391, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043685, encodeId=8a201043685c2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997362, encodeId=13fc99e36257, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jul 07 23:42:01 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1687760, encodeId=e8a9168e7604f, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Feb 07 03:13:22 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831231, encodeId=efb618312310a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Apr 17 09:13:22 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294043, encodeId=6e691294043e6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379420, encodeId=3f1c13e94206c, content=<a href='/topic/show?id=fddf803043' target=_blank style='color:#2F92EE;'>#GIP和GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8030, encryptionId=fddf803043, topicName=GIP和GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422760, encodeId=090f1422e6028, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627858, encodeId=fca0162e858f6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997417, encodeId=d6a999e417bf, content=<a href='/topic/show?id=f5cd1e48099' target=_blank style='color:#2F92EE;'>#tirzepatide#</a> 87-92%患者HbA1c小于7.0%,使用tirzepatide 5mg,平均HbA1c比基线下降1.87%;使用10mg、15mg,平均<a href='/topic/show?id=7d03849539' target=_blank style='color:#2F92EE;'>#HbA1c#</a>比基线下降1.89%与2.07%,而且体重降低7-10kg,太厉害!即使是低剂量,对于糖化血红蛋白降低水平也几乎是所有药物中最牛的。将来若再与<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>联用,几乎是攻无不克了!也可以说是近年来<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>领域划时代药物之一,这也表明,双靶点制剂,成为国际的热点,也是未来和希望所在,不仅仅是肿瘤,慢病同样如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17480, encryptionId=f5cd1e48099, topicName=tirzepatide), TopicDto(id=8495, encryptionId=7d03849539, topicName=HbA1c), TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Thu Jul 08 08:43:43 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034383, encodeId=f0b6103438391, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043685, encodeId=8a201043685c2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997362, encodeId=13fc99e36257, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jul 07 23:42:01 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1687760, encodeId=e8a9168e7604f, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Feb 07 03:13:22 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831231, encodeId=efb618312310a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Apr 17 09:13:22 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294043, encodeId=6e691294043e6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379420, encodeId=3f1c13e94206c, content=<a href='/topic/show?id=fddf803043' target=_blank style='color:#2F92EE;'>#GIP和GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8030, encryptionId=fddf803043, topicName=GIP和GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422760, encodeId=090f1422e6028, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627858, encodeId=fca0162e858f6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997417, encodeId=d6a999e417bf, content=<a href='/topic/show?id=f5cd1e48099' target=_blank style='color:#2F92EE;'>#tirzepatide#</a> 87-92%患者HbA1c小于7.0%,使用tirzepatide 5mg,平均HbA1c比基线下降1.87%;使用10mg、15mg,平均<a href='/topic/show?id=7d03849539' target=_blank style='color:#2F92EE;'>#HbA1c#</a>比基线下降1.89%与2.07%,而且体重降低7-10kg,太厉害!即使是低剂量,对于糖化血红蛋白降低水平也几乎是所有药物中最牛的。将来若再与<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>联用,几乎是攻无不克了!也可以说是近年来<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>领域划时代药物之一,这也表明,双靶点制剂,成为国际的热点,也是未来和希望所在,不仅仅是肿瘤,慢病同样如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17480, encryptionId=f5cd1e48099, topicName=tirzepatide), TopicDto(id=8495, encryptionId=7d03849539, topicName=HbA1c), TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Thu Jul 08 08:43:43 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034383, encodeId=f0b6103438391, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043685, encodeId=8a201043685c2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997362, encodeId=13fc99e36257, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jul 07 23:42:01 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-09 yibei
  6. [GetPortalCommentsPageByObjectIdResponse(id=1687760, encodeId=e8a9168e7604f, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Feb 07 03:13:22 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831231, encodeId=efb618312310a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Apr 17 09:13:22 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294043, encodeId=6e691294043e6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379420, encodeId=3f1c13e94206c, content=<a href='/topic/show?id=fddf803043' target=_blank style='color:#2F92EE;'>#GIP和GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8030, encryptionId=fddf803043, topicName=GIP和GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422760, encodeId=090f1422e6028, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627858, encodeId=fca0162e858f6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997417, encodeId=d6a999e417bf, content=<a href='/topic/show?id=f5cd1e48099' target=_blank style='color:#2F92EE;'>#tirzepatide#</a> 87-92%患者HbA1c小于7.0%,使用tirzepatide 5mg,平均HbA1c比基线下降1.87%;使用10mg、15mg,平均<a href='/topic/show?id=7d03849539' target=_blank style='color:#2F92EE;'>#HbA1c#</a>比基线下降1.89%与2.07%,而且体重降低7-10kg,太厉害!即使是低剂量,对于糖化血红蛋白降低水平也几乎是所有药物中最牛的。将来若再与<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>联用,几乎是攻无不克了!也可以说是近年来<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>领域划时代药物之一,这也表明,双靶点制剂,成为国际的热点,也是未来和希望所在,不仅仅是肿瘤,慢病同样如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17480, encryptionId=f5cd1e48099, topicName=tirzepatide), TopicDto(id=8495, encryptionId=7d03849539, topicName=HbA1c), TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Thu Jul 08 08:43:43 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034383, encodeId=f0b6103438391, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043685, encodeId=8a201043685c2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997362, encodeId=13fc99e36257, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jul 07 23:42:01 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1687760, encodeId=e8a9168e7604f, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Feb 07 03:13:22 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831231, encodeId=efb618312310a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Apr 17 09:13:22 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294043, encodeId=6e691294043e6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379420, encodeId=3f1c13e94206c, content=<a href='/topic/show?id=fddf803043' target=_blank style='color:#2F92EE;'>#GIP和GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8030, encryptionId=fddf803043, topicName=GIP和GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422760, encodeId=090f1422e6028, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627858, encodeId=fca0162e858f6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997417, encodeId=d6a999e417bf, content=<a href='/topic/show?id=f5cd1e48099' target=_blank style='color:#2F92EE;'>#tirzepatide#</a> 87-92%患者HbA1c小于7.0%,使用tirzepatide 5mg,平均HbA1c比基线下降1.87%;使用10mg、15mg,平均<a href='/topic/show?id=7d03849539' target=_blank style='color:#2F92EE;'>#HbA1c#</a>比基线下降1.89%与2.07%,而且体重降低7-10kg,太厉害!即使是低剂量,对于糖化血红蛋白降低水平也几乎是所有药物中最牛的。将来若再与<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>联用,几乎是攻无不克了!也可以说是近年来<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>领域划时代药物之一,这也表明,双靶点制剂,成为国际的热点,也是未来和希望所在,不仅仅是肿瘤,慢病同样如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17480, encryptionId=f5cd1e48099, topicName=tirzepatide), TopicDto(id=8495, encryptionId=7d03849539, topicName=HbA1c), TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Thu Jul 08 08:43:43 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034383, encodeId=f0b6103438391, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043685, encodeId=8a201043685c2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997362, encodeId=13fc99e36257, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jul 07 23:42:01 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-08 小小医者

    #tirzepatide# 87-92%患者HbA1c小于7.0%,使用tirzepatide 5mg,平均HbA1c比基线下降1.87%;使用10mg、15mg,平均#HbA1c#比基线下降1.89%与2.07%,而且体重降低7-10kg,太厉害!即使是低剂量,对于糖化血红蛋白降低水平也几乎是所有药物中最牛的。将来若再与#二甲双胍#联用,几乎是攻无不克了!也可以说是近年来#糖尿病#领域划时代药物之一,这也表明,双靶点制剂,成为国际的热点,也是未来和希望所在,不仅仅是肿瘤,慢病同样如此

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1687760, encodeId=e8a9168e7604f, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Feb 07 03:13:22 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831231, encodeId=efb618312310a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Apr 17 09:13:22 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294043, encodeId=6e691294043e6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379420, encodeId=3f1c13e94206c, content=<a href='/topic/show?id=fddf803043' target=_blank style='color:#2F92EE;'>#GIP和GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8030, encryptionId=fddf803043, topicName=GIP和GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422760, encodeId=090f1422e6028, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627858, encodeId=fca0162e858f6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997417, encodeId=d6a999e417bf, content=<a href='/topic/show?id=f5cd1e48099' target=_blank style='color:#2F92EE;'>#tirzepatide#</a> 87-92%患者HbA1c小于7.0%,使用tirzepatide 5mg,平均HbA1c比基线下降1.87%;使用10mg、15mg,平均<a href='/topic/show?id=7d03849539' target=_blank style='color:#2F92EE;'>#HbA1c#</a>比基线下降1.89%与2.07%,而且体重降低7-10kg,太厉害!即使是低剂量,对于糖化血红蛋白降低水平也几乎是所有药物中最牛的。将来若再与<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>联用,几乎是攻无不克了!也可以说是近年来<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>领域划时代药物之一,这也表明,双靶点制剂,成为国际的热点,也是未来和希望所在,不仅仅是肿瘤,慢病同样如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17480, encryptionId=f5cd1e48099, topicName=tirzepatide), TopicDto(id=8495, encryptionId=7d03849539, topicName=HbA1c), TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Thu Jul 08 08:43:43 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034383, encodeId=f0b6103438391, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043685, encodeId=8a201043685c2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997362, encodeId=13fc99e36257, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jul 07 23:42:01 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-08 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1687760, encodeId=e8a9168e7604f, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Feb 07 03:13:22 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831231, encodeId=efb618312310a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Apr 17 09:13:22 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294043, encodeId=6e691294043e6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379420, encodeId=3f1c13e94206c, content=<a href='/topic/show?id=fddf803043' target=_blank style='color:#2F92EE;'>#GIP和GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8030, encryptionId=fddf803043, topicName=GIP和GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422760, encodeId=090f1422e6028, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627858, encodeId=fca0162e858f6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997417, encodeId=d6a999e417bf, content=<a href='/topic/show?id=f5cd1e48099' target=_blank style='color:#2F92EE;'>#tirzepatide#</a> 87-92%患者HbA1c小于7.0%,使用tirzepatide 5mg,平均HbA1c比基线下降1.87%;使用10mg、15mg,平均<a href='/topic/show?id=7d03849539' target=_blank style='color:#2F92EE;'>#HbA1c#</a>比基线下降1.89%与2.07%,而且体重降低7-10kg,太厉害!即使是低剂量,对于糖化血红蛋白降低水平也几乎是所有药物中最牛的。将来若再与<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>联用,几乎是攻无不克了!也可以说是近年来<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>领域划时代药物之一,这也表明,双靶点制剂,成为国际的热点,也是未来和希望所在,不仅仅是肿瘤,慢病同样如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17480, encryptionId=f5cd1e48099, topicName=tirzepatide), TopicDto(id=8495, encryptionId=7d03849539, topicName=HbA1c), TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Thu Jul 08 08:43:43 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034383, encodeId=f0b6103438391, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043685, encodeId=8a201043685c2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997362, encodeId=13fc99e36257, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jul 07 23:42:01 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-08 misszhang

    谢谢MedSci提供最新的资讯

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1687760, encodeId=e8a9168e7604f, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Mon Feb 07 03:13:22 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831231, encodeId=efb618312310a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Apr 17 09:13:22 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294043, encodeId=6e691294043e6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379420, encodeId=3f1c13e94206c, content=<a href='/topic/show?id=fddf803043' target=_blank style='color:#2F92EE;'>#GIP和GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8030, encryptionId=fddf803043, topicName=GIP和GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422760, encodeId=090f1422e6028, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627858, encodeId=fca0162e858f6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jul 09 14:13:22 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997417, encodeId=d6a999e417bf, content=<a href='/topic/show?id=f5cd1e48099' target=_blank style='color:#2F92EE;'>#tirzepatide#</a> 87-92%患者HbA1c小于7.0%,使用tirzepatide 5mg,平均HbA1c比基线下降1.87%;使用10mg、15mg,平均<a href='/topic/show?id=7d03849539' target=_blank style='color:#2F92EE;'>#HbA1c#</a>比基线下降1.89%与2.07%,而且体重降低7-10kg,太厉害!即使是低剂量,对于糖化血红蛋白降低水平也几乎是所有药物中最牛的。将来若再与<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>联用,几乎是攻无不克了!也可以说是近年来<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>领域划时代药物之一,这也表明,双靶点制剂,成为国际的热点,也是未来和希望所在,不仅仅是肿瘤,慢病同样如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17480, encryptionId=f5cd1e48099, topicName=tirzepatide), TopicDto(id=8495, encryptionId=7d03849539, topicName=HbA1c), TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Thu Jul 08 08:43:43 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034383, encodeId=f0b6103438391, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043685, encodeId=8a201043685c2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 08 02:13:22 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997362, encodeId=13fc99e36257, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jul 07 23:42:01 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-07 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

JCEM:质子泵抑制剂对血糖控制和糖尿病事件的影响

接受PPI治疗改善了糖尿病患者的血糖指数,但并未改变糖尿病发生风险。因此,在给糖尿病患者开抗酸药时,应考虑PPI对血糖控制的影响。

NEJM:长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用

对于伴有肾脏疾病以及心血管事件风险的II型糖尿病患者,每周1次Efpeglenatide治疗可显著降低患者主要心血管事件以及肾脏事件风险。

NEJM:Tirzepatide头对头III期研究成功 降糖减重效果优于索马鲁肽

对于II型糖尿病患者,GLP-1R, GIPR双重激动剂Tirzepatide在改善血糖,降低体重方面的效果优于索马鲁肽。

JAHA:糖尿病与青年和中年卒中幸存者的住院和长期预后不良相关

对于65岁以下既往有糖尿病的卒中患者长期预后不佳的问题可能需要重点进行二级预防和危险因素管理。

SoliMix结果公布:基础胰岛素与GLP-1RA的复方制剂与预混胰岛素的头对头比较研究

随着新技术、新疗法及相关循证证据的不断涌现,近年来糖尿病治疗日新月异。 对糖尿病患者而言,血糖监测是实现血糖控制达标的重要手段之一。 对于2型糖尿病的药物治疗,多项指南再次强调了以患者为中心指导药物的

JAMA Intern Med:SGLT-2抑制剂 vs磺脲类药物对II型糖尿病患者死亡风险的影响

与磺脲类药物相比,使用二甲双胍-SGLT-2抑制剂联合治疗可降低II型糖尿病患者的全因死亡风险

拓展阅读

显著减脂、少掉肌肉!最新研究:这一降糖药,竟然还有三大作用

提前公布的SURPASS-3子研究(SURPASS-3 MRI)探索性分析结果摘要揭示了上述3个关键问题的重要答案!

J Endocr Soc:Tirzepatide作为单一疗法改善2型糖尿病患者β细胞功能和胰岛素敏感性的标记物(SURPASS-1)

作为早期T2D的单药治疗,替西帕肽在胰腺β细胞功能和IS的生物标志物方面均取得了显著改善。

Lancet子刊:单用降糖药治疗效果差怎么办?胰岛素可以缓缓!试试这种新型“减肥药”!

2型糖尿病是一种以高血糖为特征的慢性代谢疾病,随着病情的发展需要逐步增加药物。tirzepatide(替西帕肽)是一种39个氨基酸的合成肽,对GIP和GLP-1受体具有激动剂活性。

Tirzepatide(替西帕肽)中国申报上市,是当下降糖之王!

2022年9月7日,礼来GLP-1R/GIPR双靶点激动剂Tirzepatide(替尔泊肽)注射液的上市申请获得NMPA受理。

柳叶刀:Tirzepatide控制T2DM患者血糖的效果优于胰岛素,且不增加心血管疾病风险!

在心血管疾病风险升高的2型糖尿病患者中,与甘精胰岛素相比,Tirzepatide显示出更大且具有临床意义的降低HbA1c的效果,同时还可降低低血糖的发生率

NEJM:Tirzepatide头对头III期研究成功 降糖减重效果优于索马鲁肽

对于II型糖尿病患者,GLP-1R, GIPR双重激动剂Tirzepatide在改善血糖,降低体重方面的效果优于索马鲁肽。